| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036147451 |
| P356 | DOI | 10.1007/S00115-007-2261-9 |
| P698 | PubMed publication ID | 17551708 |
| P50 | author | Sven G Meuth | Q88461559 |
| Heinz Wiendl | Q27583547 | ||
| Christoph Kleinschnitz | Q67221107 | ||
| P2093 | author name string | B C Kieseier | |
| P2860 | cites work | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | Q22252943 |
| Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. | Q24541522 | ||
| Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial | Q71607051 | ||
| Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis | Q71656662 | ||
| Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model | Q72027792 | ||
| Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis | Q72114028 | ||
| Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand | Q73035541 | ||
| Statins as a newly recognized type of immunomodulator | Q73252634 | ||
| Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor | Q73270598 | ||
| Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand | Q73401367 | ||
| The ups and downs of multiple sclerosis therapeutics | Q73652320 | ||
| Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators | Q73766375 | ||
| Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis | Q73934385 | ||
| Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group | Q74038855 | ||
| Multiple sclerosis: a two-stage disease | Q74433993 | ||
| Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1beta release via suppressed processing of proIL-1beta, whereas TNF-alpha release is inhibited on the level of proTNF-alpha formation | Q74456315 | ||
| Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation | Q74775333 | ||
| Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats | Q77402575 | ||
| Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis | Q77671554 | ||
| A novel targeted T-cell modulator, efalizumab, for plaque psoriasis | Q79308555 | ||
| Treatment of active secondary progressive multiple sclerosis with treosulfan | Q80188566 | ||
| Efalizumab | Q80235396 | ||
| Natalizumab and PML | Q81273174 | ||
| Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis | Q81401055 | ||
| Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis | Q81621817 | ||
| Ia-expressing microglial cells in experimental allergic encephalomyelitis in rats | Q69197298 | ||
| Vaccination against autoimmune encephalomyelitis (EAE): Attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line | Q71064647 | ||
| Differential requirements for alpha4 integrins during fetal and adult hematopoiesis | Q71170504 | ||
| Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity | Q71396691 | ||
| IL-12 deaths: explanation and a puzzle | Q71542131 | ||
| Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis | Q71586107 | ||
| Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis | Q24555084 | ||
| IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel | Q24646531 | ||
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy | Q24683776 | ||
| Effect of pioglitazone treatment in a patient with secondary multiple sclerosis | Q24794380 | ||
| Pathogenetic role of autoantibodies in neurological diseases | Q28138484 | ||
| Cannabinoids control spasticity and tremor in a multiple sclerosis model | Q28138564 | ||
| Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis | Q28144207 | ||
| Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system | Q28144436 | ||
| Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event | Q28186287 | ||
| Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion | Q28253124 | ||
| Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis | Q28255548 | ||
| Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease | Q28255557 | ||
| Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis | Q28574796 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| Multiple sclerosis | Q29616022 | ||
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis | Q29616119 | ||
| Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists | Q29618071 | ||
| The many roles of chemokines and chemokine receptors in inflammation | Q29618880 | ||
| Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self | Q29619194 | ||
| Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 | Q29619644 | ||
| Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 | Q29622893 | ||
| Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences | Q30652634 | ||
| The role of magnetic resonance imaging in the assessment of patients with established multiple sclerosis. | Q30742091 | ||
| Emerging therapies in multiple sclerosis | Q31015100 | ||
| Efalizumab: a review of events reported during clinical trials and side effects | Q33370375 | ||
| The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation | Q33652505 | ||
| Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. | Q33774221 | ||
| CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris | Q33855058 | ||
| Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. | Q33874321 | ||
| Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones | Q33909622 | ||
| Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. | Q33941343 | ||
| Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo | Q34049368 | ||
| Update on the therapeutic potential of PDE4 inhibitors | Q34107488 | ||
| Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis | Q34109903 | ||
| Treatment of multiple sclerosis with the pregnancy hormone estriol | Q34151750 | ||
| Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches | Q34156542 | ||
| Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation | Q34178136 | ||
| Role of costimulatory molecules in autoimmunity. | Q34233359 | ||
| High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis | Q34237823 | ||
| Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators | Q34322193 | ||
| Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity | Q34334271 | ||
| Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? | Q34348969 | ||
| Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. | Q34405210 | ||
| Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity | Q34448370 | ||
| The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses | Q34468846 | ||
| Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta | Q34514715 | ||
| Activation and inhibition of lymphocytes by costimulation | Q34517906 | ||
| The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses | Q34542227 | ||
| Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial | Q34543217 | ||
| Oral fingolimod (FTY720) for relapsing multiple sclerosis | Q34565985 | ||
| Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. | Q34596171 | ||
| Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. | Q34710256 | ||
| Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials | Q34725775 | ||
| BX-471 Berlex | Q34757500 | ||
| Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases | Q35071710 | ||
| Sirolimus: its discovery, biological properties, and mechanism of action | Q35125746 | ||
| Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. | Q35196338 | ||
| Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis | Q35325861 | ||
| Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? | Q35688221 | ||
| Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients | Q35824531 | ||
| Mycophenolate mofetil in multiple sclerosis | Q35835852 | ||
| Erythropoietin as a novel neuroprotectant. | Q35844687 | ||
| Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines | Q35861182 | ||
| Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders? | Q35891574 | ||
| Na+ channel expression along axons in multiple sclerosis and its models | Q35921669 | ||
| New directions in MS therapeutics: vehicles of hope | Q35941887 | ||
| Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). | Q37381231 | ||
| A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis | Q37611832 | ||
| Manipulation of T-cell responses with monoclonal antibodies | Q38201549 | ||
| Functional Interactions of Neurotrophins and Neurotrophin Receptors | Q40441056 | ||
| Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis | Q40511405 | ||
| Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. | Q40587768 | ||
| Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. | Q40610521 | ||
| Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. | Q40637757 | ||
| The immune modulator FTY720 targets sphingosine 1-phosphate receptors | Q40736684 | ||
| An open trial of OKT3 in patients with multiple sclerosis | Q40747081 | ||
| Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination | Q40831654 | ||
| Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases | Q40908008 | ||
| Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats | Q41348774 | ||
| Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone. | Q41577458 | ||
| A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis | Q41728578 | ||
| Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis | Q41788436 | ||
| Myeloablative and immunosuppressive properties of treosulfan in mice | Q42168522 | ||
| TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs | Q42181372 | ||
| T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study | Q42692324 | ||
| Suppressor T cells in human diseases | Q42971257 | ||
| Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. | Q43668453 | ||
| Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage | Q43708042 | ||
| Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. | Q43746298 | ||
| Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides | Q43794379 | ||
| First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients | Q43931513 | ||
| The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease | Q43934617 | ||
| Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis | Q44002202 | ||
| The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis | Q44133715 | ||
| Statins as immunomodulators: comparison with interferon-beta 1b in MS. | Q44172256 | ||
| The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study | Q44244034 | ||
| Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes | Q44251886 | ||
| Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions | Q44310002 | ||
| Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment | Q44370378 | ||
| Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination | Q44477086 | ||
| Cladribine in treatment of chronic progressive multiple sclerosis | Q44496335 | ||
| Cannabinoids inhibit neurodegeneration in models of multiple sclerosis | Q44522438 | ||
| Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo | Q44540512 | ||
| Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes | Q44641631 | ||
| Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector | Q44779663 | ||
| Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs | Q44801480 | ||
| Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship | Q44823676 | ||
| Axonal protection using flecainide in experimental autoimmune encephalomyelitis. | Q44880213 | ||
| Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. | Q44880234 | ||
| Oral simvastatin treatment in relapsing-remitting multiple sclerosis | Q44897670 | ||
| Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis | Q45008706 | ||
| Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion | Q45029733 | ||
| Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. | Q45076768 | ||
| Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life | Q45152665 | ||
| The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. | Q45229482 | ||
| Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis | Q45303266 | ||
| Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up | Q45417845 | ||
| Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis | Q46266579 | ||
| Lipoic acid in multiple sclerosis: a pilot study | Q46407394 | ||
| Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes | Q46460140 | ||
| Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention | Q46499427 | ||
| Erythropoietin: novel approaches to neuroprotection in human brain disease | Q35956310 | ||
| The promise of minocycline in neurology. | Q35958974 | ||
| Autologous haematopoietic-stem-cell transplantation for multiple sclerosis | Q35994389 | ||
| Other therapy options and future strategies for treating patients with multiple sclerosis | Q35995796 | ||
| Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs | Q36072414 | ||
| Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. | Q36074419 | ||
| Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease | Q36107645 | ||
| Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab | Q36148448 | ||
| The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms | Q36205278 | ||
| Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? | Q36211855 | ||
| Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis | Q36226307 | ||
| CTLA-4 is a second receptor for the B cell activation antigen B7 | Q36230356 | ||
| Natalizumab for the treatment of multiple sclerosis and Crohn's disease | Q36284072 | ||
| Cladribine for multiple sclerosis: review and current status | Q36307847 | ||
| Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance | Q36318980 | ||
| Antigen-specific therapies in multiple sclerosis. | Q36327373 | ||
| Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides | Q36327377 | ||
| Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction | Q36368672 | ||
| Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis | Q36384922 | ||
| Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. | Q36402704 | ||
| Lymphoid neogenesis in chronic inflammatory diseases. | Q36405080 | ||
| Multiple sclerosis--the plaque and its pathogenesis | Q36410882 | ||
| Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases | Q36438898 | ||
| The value of animal models for drug development in multiple sclerosis. | Q36458937 | ||
| T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells | Q36475992 | ||
| Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro | Q37126896 | ||
| Effective combination of minocycline and interferon-beta in a model of multiple sclerosis | Q46548808 | ||
| Graft-versus-host disease prevention by rapamycin: cellular mechanisms | Q46600793 | ||
| Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients | Q46740179 | ||
| The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group | Q48135012 | ||
| Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis | Q48383559 | ||
| A controlled trial of natalizumab for relapsing multiple sclerosis | Q48414534 | ||
| Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody | Q48442189 | ||
| Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis | Q48475566 | ||
| Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study | Q48488976 | ||
| A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses | Q48602930 | ||
| Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial | Q48647481 | ||
| MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis | Q48671716 | ||
| Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. | Q48851709 | ||
| A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. | Q48967659 | ||
| Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. | Q48974951 | ||
| Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. | Q49014751 | ||
| Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis | Q50127386 | ||
| T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. | Q50749623 | ||
| Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. | Q50930145 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| The effect of cladribine on T(1) 'black hole' changes in progressive MS. | Q53909697 | ||
| Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients. | Q53991755 | ||
| Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. | Q54128490 | ||
| Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. | Q54481809 | ||
| The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. | Q54585384 | ||
| Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. | Q54694225 | ||
| Natalizumab effects on immune cell responses in multiple sclerosis | Q57041915 | ||
| Do myelin-directed antibodies predict multiple sclerosis? | Q57042143 | ||
| Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial | Q57101760 | ||
| Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels | Q57839822 | ||
| Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial | Q57911989 | ||
| Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial | Q57911995 | ||
| Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis | Q57997698 | ||
| Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis | Q59273850 | ||
| Glutamate excitotoxicity in a model of multiple sclerosis | Q60450917 | ||
| Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange | Q61709608 | ||
| Selective and antigen-dependent effects of myelin degeneration on central nervous system inflammation | Q61709613 | ||
| Multiple sclerosis: trapped in deadly glue | Q61853106 | ||
| P433 | issue | 8 | |
| P921 | main subject | immunotherapy | Q1427096 |
| multiple sclerosis | Q8277 | ||
| P304 | page(s) | 883-911 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Der Nervenarzt | Q15446312 |
| P1476 | title | [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis] | |
| P478 | volume | 78 |
| Q51958899 | [Targeting B cells in multiple sclerosis. Current concepts and strategies]. | cites work | P2860 |
Search more.